685 W. Baltimore St.
Education and Training
University of Wisconsin-Madison, B.S., Medical Microbiology and Immunology, 2004
University of Wisconsin School of Medicine and Public Health, M.D., 2009
Residency, University of Minnesota, Pediatrics, 2012
Fellowship, University of Maryland School of Medicine, Pediatric Infectious Diseases, 2019
University of Maryland, Baltimore, M.S., Epidemiology and Clinical Research, 2023
Dr. Friedman-Klabanoff is a board-certified pediatric infectious disease specialist with a primary research interest in malaria vaccine development and natural and vaccine-induced immunity to Plasmodium falciparum, the most common and deadly cause of malaria worldwide. She helped to lead a Phase I trial of a new malaria vaccine candidate based on the full-length circumsporozoite protein, examining the safety, immunogenicity and preliminary efficacy against controlled human malaria infection. Leveraging samples from this trial, Dr. Friedman-Klabanoff will examine the humoral immune responses to this vaccine on a peptide microarray to determine if those protected from infection have different antibody responses to the vaccine than those who are not. She is utilizing the peptide array platform to examine natural immunity to the pre-erythrocytic stages of malaria and protection from infection in a cohort of children in Malawi, supported by a K23 from the National Institute of Allergy and Infectious Diseases under the mentorship of Dr. Miriam Laufer. The overall goal of these projects is to examine the fine specificity and in vitro functional activity of pre-erythrocytic antibodies to refine future malaria vaccine efforts.
During the COVID-19 pandemic, Dr. Friedman-Klabanoff has expanded her research to also study the use of serological assays to track the spread of SARS-CoV-2 in the community through the COVID-19 Community Research Partnership. She also conducts vaccine trials for malaria, mosquito-borne diseases, and SARS-CoV-2.
Malaria, malaria vaccine development, humoral immunity, SARS-CoV-2 serology, clinical vaccine trials, peptide microarray, human challenge studies, controlled human infection
Friedman-Klabanoff DJ, Birkhold M, Short MT, Wilson TR, Meneses CR, Lacsina JR, Oliveira F, Kamhawi S, Valenzuela JG, Hunsberger S, Mateja A, Stoloff G, Pleguezuelos O, Memoli MJ, Laurens MB. Safety and immunogenicity of AGS-v PLUS, a mosquito saliva peptide vaccine against arboviral diseases: A randomized, double-blind, placebo-controlled Phase 1 trial. EBioMedicine. 2022 Nov 24;86:104375. doi: 10.1016/j.ebiom.2022.104375. Online ahead of print. PMID: 36436281.
Friedman-Klabanoff DJ, Fitzpatrick MC, Deming ME, Agrawal V, Sitar S, Schaafsma T, Brown E, Neuzil KM, Barnabas RV, Laufer MK; Hydroxychloroquine COVID-19 PEP Study Team. Risk of SARS-CoV-2 acquisition is associated with individual exposure but not community-level transmission. J Infect Dis. 2022 Feb 2:jiac029. doi: 10.1093/infdis/jiac029. Online ahead of print. PMID: 35134185.
Friedman-Klabanoff DJ, Berry AA, Travassos MA, Cox C, Zhou Y, Mo AX, Nomicos EYH, Deye GA, Pasetti MF, Laurens MB. Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in Phase 1 first-in-human clinical testing. 2021 Feb 22;39(8): 1195-1200. doi: 10.1016/j.vaccine.2020.12.023. Epub 2021 Jan 22. PMID: 33494963.
Friedman-Klabanoff DJ, Travassos MA, Ifeonu OO, Agrawal S, Ouattara A, Pike A, Bailey JA, Adams M, Coulibaly D, Lyke KE, Laurens MB, Takala-Harrison S, Kouriba B, Kone AK, Doumbo OK, Patel JJ, Thera MA, Felgner PL, Tan JC, Plowe CV, Berry AA. Epitope-specific antibody responses to a Plasmodium falciparum subunit vaccine target in a malaria-endemic population. J Infect Dis. 2021 Jun 4;223(11): 1943-1947. doi:10.1093/infdis/jiaa611. PMID: 32992328.
Friedman-Klabanoff DJ, Laurens MB, Berry AA, Travassos MA, Adams M, Strauss KA, Shrestha B, Levine MM, Edelman R, Lyke KE. The controlled human malaria infection experience at the University of Maryland. Am J Trop Med Hyg. 2019; 100(3): 556-565.
Friedman-Klabanoff DJ, Campbell JD. A 29-day-old Infant with Poor Feeding and a Rash. Pediatr Rev. 2021 Jan;42(Suppl 1):S15-S18. doi: 10.1542/pir.2019-0096.
Dr. Friedman-Klabanoff is a board-certified pediatric infectious disease specialist. She attends on the pediatric infectious disease consult service, on which she also teaches medical students, residents, and fellows.
2018 – 2020, 2021-2023 National Institutes of Health Loan Repayment Program
2019 – 2021 Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene Postdoctoral Fellowship in Tropical Infectious Diseases
2019 – 2021 Pichichero Family Foundation Research Development, Vaccines for Children Initiative Award in Pediatric Infectious Diseases
2021 - 2023 Passano Foundation Clinician-Investigator Award for Career Development
Dr. Friedman-Klabanoff works on numerous contracts; a select number are included below. Please refer to her CV for a full listing.